New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 20, 2015
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
06:22 EDTJCPJ.C. Penney to bring back 120-page catalog, WSJ reports
J.C. Penney has decided to resurrect its catalog in the form of a 120-page book that will mark the first catalog the chain has sent out since 2010, The Wall Street Journal reports. The retailer, which quit the catalog amid a broader pullback caused by the recession and the rise of e-commerce, now believes the catalog can help drive web sales. Reference Link
January 16, 2015
16:29 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
16:07 EDTIQNTInteliquent CEO Edward Evans to depart company
Inteliquent announced that G. Edward Evans will be departing as the company's CEO in order to pursue other interests. Evans' employment agreement is set to expire on March 31. However, the company and Evans anticipate that Evans will continue to act as the company's CEO beyond such date if necessary to permit the company to complete a nationwide search for his successor. In addition, it is anticipated that Evans will resign as a member of the company's board upon his departure as CEO.
16:00 EDTPBROptions Update; January 16, 2015
Subscribe for More Information
13:01 EDTJNJEarnings Preview: Johnson & Johnson reports after recent Goldman downgrade
Subscribe for More Information
12:43 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
10:13 EDTVNOBofA/Merrill Office REITs analyst holds analyst/industry conference call
U.S. Office & Warehouse REIT Analyst Feldman, along with Jones Lang LaSalle (JLL) Research, Lasing and Capital Markets teams, provide a comprehensive update on leasing and capital market conditions ahead of earnings on an Analyst/Industry conference call to be held on January 20 at 11 am.
08:58 EDTJNJRoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
08:12 EDTJNJJohnson & Johnson forms Ebola vaccine development consortia
Subscribe for More Information
07:23 EDTCATJim Chanos says long shares of Apple
Subscribe for More Information
07:16 EDTCATCaterpillar January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
07:12 EDTCATChanos says two of three Caterpillar areas 'highly troubled'
Subscribe for More Information
January 15, 2015
16:31 EDTVNOUrban Edge announces completion of spin-off from Vornado
Subscribe for More Information
16:08 EDTJNJJ&J unit sells U.S. Nucynta license rights to Depomed for $1.05B
Subscribe for More Information
16:08 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
Subscribe for More Information
16:05 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use